Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.28 98.75 0.68%
TOPIX 1,170.50 3.91 0.34%
HANG SENG 22,760.24 64.23 0.28%

Abbott Announces FDA Approval and U.S. Launch of the TECNIS® Toric Intraocular Lens for Cataract Patients



Abbott Announces FDA Approval and U.S. Launch of the TECNIS® Toric Intraocular
                          Lens for Cataract Patients

  PR Newswire

  ABBOTT PARK, Illinois, April 18, 2013

ABBOTT PARK, Illinois, April 18, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today
announced that the TECNIS® Toric 1-Piece intraocular lens (IOL) has received
U.S. Food and Drug Administration (FDA) approval and is launching in the
United States for the treatment of cataract patients with pre-existing corneal
astigmatism.

Corneal astigmatism is a condition where the curvature of the cornea is
uneven, preventing light rays from focusing clearly on the retina, resulting
in blurred vision. Intraocular lenses are implanted in a patient's eye after
the removal of the natural lens that has become clouded by a cataract. Unlike
conventional IOLs, the TECNIS Toric 1-Piece IOL can correct a patient's loss
of focus due to pre-existing corneal astigmatism of one diopter (a unit of
measurement of the refractive power of a lens) or greater.

The average age for the cataract surgery patient in the United States is
approximately 68 years with more than 3.5 million procedures performed
annually. As the U.S. population continues to age, the number of cataract
surgeries is expected to grow nearly 3 percent each year, increasing patient
demand for improved, precise visual outcomes and independence from glasses.

"The TECNIS Toric 1-Piece IOL represents the latest advancement in cataract
technology and expands Abbott's portfolio of the TECNIS family of IOLs," said
Murthy Simhambhatla, senior vice president, Medical Optics, Abbott. "The
TECNIS Toric 1-Piece IOL allows surgeons to offer an additional lens option
that provides proven visual outcomes to increase patient satisfaction."

Along with delivering precise visual outcomes for patients, rotational
stability is an important attribute of a toric IOL. The TECNIS Toric 1-piece
IOL remains very stable once inserted into the eye, and meets the new standard
for toric IOL rotational stability, as approved by the American National
Standards Institute (ANSI).

In addition to providing astigmatism correction, the TECNIS Toric 1-Piece lens
minimizes imprecise light focusing (spherical aberration) to provide sharper
distance vision for the patient.

"The TECNIS Toric IOL decreases astigmatism while improving visual quality,
with improved functional vision," said Kevin Waltz, O.D., M.D., Eye Surgeons
of Indiana, and clinical investigator for the TECNIS Toric IOL. "Having
implanted several TECNIS Toric IOLs within clinical trials, I find it delivers
excellent patient results."

Additional information about the TECNIS Toric 1-Piece IOL, including important
safety information, is available at www.tecnistoriciol.com .

About Abbott Medical Optics (AMO)

Abbott Medical Optics is focused on delivering life-improving vision
technologies to people of all ages. The company offers a comprehensive
portfolio of cataract, refractive and eye care products. Products in the
cataract line include monofocal and multifocal intraocular lenses (IOLs),
phacoemulsification systems, viscoelastics, and related products used in
ocular surgery. Products in the refractive line include wavefront diagnostic
devices, femtosecond lasers and associated patient interface devices; excimer
laser vision correction systems and treatment cards. Products in the eye care
line include disinfecting solutions, enzymatic cleaners, lens rewetting drops
and artificial tears. For more information, please visit
www.abbottmedicaloptics.com .

About Abbott

Abbott is a global healthcare company devoted to improving life through the
development of products and technologies that span the breadth of
healthcare. With a portfolio of leading, science-based offerings in
diagnostics, medical devices, nutritionals and branded generic
pharmaceuticals, Abbott serves people in more than 150 countries and employs
approximately 70,000 people. 

Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.

Website: http://www.abbott.com
Website: http://www.abbottmedicaloptics.com
Contact: Media, Steve Chesterman, +1-714-247-8711, or Financial, Tina Ventura,
+1-847-935-9390
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement